Grail's Multi-Cancer Blood Test Moves Closer to Real-World Use Despite Trial Setback
Despite missing a primary endpoint in its NHS trial for detecting early-stage cancers, Grail (NASDAQ: GRAL) continues to push forward with regulatory and insurance coverage goals. The company’s Galleri test aims to detect over 50 types of cancer at an earlier stage, potentially reducing treatment costs.
Topics: cancer screening FDA approval Grail (NASDAQ: GRAL) stock analysis